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ARTICLE
Cooperation of cancer drivers with regulatory
germline variants shapes clinical outcomes
Julian Musa 1, Florencia Cidre-Aranaz1, Marie-Ming Aynaud2, Martin F. Orth 1, Maximilian M.L. Knott 1,3,
Olivier Mirabeau2, Gal Mazor4, Mor Varon4, Tilman L.B. Hölting 1, Sandrine Grossetête2, Moritz Gartlgruber5,
Didier Surdez 2, Julia S. Gerke1, Shunya Ohmura 1, Aruna Marchetto 1, Marlene Dallmayer 1,
Michaela C. Baldauf1, Stefanie Stein1, Giuseppina Sannino1, Jing Li1, Laura Romero-Pérez 1,
Frank Westermann 5, Wolfgang Hartmann 6, Uta Dirksen7, Melissa Gymrek 8,9,
Nathaniel D. Anderson 10,11, Adam Shlien10,11,12, Barak Rotblat 4, Thomas Kirchner3,13,14, Olivier Delattre2 &
Thomas G.P. Grünewald1,3,13,14
Pediatric malignancies including Ewing sarcoma (EwS) feature a paucity of somatic altera-
tions except for pathognomonic driver-mutations that cannot explain overt variations in
clinical outcome. Here, we demonstrate in EwS how cooperation of dominant oncogenes and
regulatory germline variants determine tumor growth, patient survival and drug response.
Binding of the oncogenic EWSR1-FLI1 fusion transcription factor to a polymorphic enhancer-
like DNA element controls expression of the transcription factor MYBL2 mediating these
phenotypes. Whole-genome and RNA sequencing reveals that variability at this locus is
inherited via the germline and is associated with variable inter-tumoral MYBL2 expression.
High MYBL2 levels sensitize EwS cells for inhibition of its upstream activating kinase CDK2
in vitro and in vivo, suggesting MYBL2 as a putative biomarker for anti-CDK2-therapy.
Collectively, we establish cooperation of somatic mutations and regulatory germline variants
as a major determinant of tumor progression and highlight the importance of integrating the
regulatory genome in precision medicine.
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The advent of high-throughput “omics” technologies inoncology enabled assignment of patients to targetedtherapies based on somatic mutations in the protein coding
genome1. However, many childhood cancers including Ewing
sarcoma (EwS)—a highly aggressive bone-associated cancer—
hardly exhibit any recurrent genetic alteration other than pathog-
nomonic and uniformly expressed driver mutations2,3. Yet, these
tumors show substantial inter-individual heterogeneity concerning
clinical behavior and treatment response, which cannot be solely
explained by their few additional (epi-)genetic alterations3–6.
Recent studies in humans and model organisms suggested that
the effects of a dominant oncogene may depend on variations in
the regulatory genome7–11. Thus, we hypothesized that oncogenic
cooperation of driver-mutations with specific regulatory germline
variants may explain inter-individual diversity of clinical out-
comes in cancer.
We explore this possibility in EwS, which constitutes a genuine
model to study such cooperation for several reasons: First, it is
characterized by a simple, nearly diploid genome with a single
driver-mutation resulting from chromosomal rearrangements
fusing the EWSR1 gene to various members of the ETS family of
transcription factors (in 85% FLI1)2,3,12–14. Second, EWSR1-FLI1
steers ~40% of its target genes by binding DNA at GGAA-
microsatellites, which are thereby converted into potent enhan-
cers15–18. Third, the enhancer activity of EWSR1-FLI1-bound
GGAA-microsatellites strongly depends on the inter-individually
variable number of consecutive GGAA-repeats16,17,19. Together,
these characteristics provide an ideal framework to analyze how
cooperation of a dominant oncogene (here EWSR1-FLI1) with
polymorphic germline regulatory elements (here GGAA-micro-
satellites) influences the expression of disease-promoting genes
that could explain clinical diversity in cancer. In this study, we
show, in the EwS model, how such cooperation steers the
expression of the functionally and clinically relevant EWSR1-FLI1
target gene MYBL2, thereby determining tumor growth, patient
survival, and drug response.
Results
EWSR1-FLI1 regulates MYBL2 via a polymorphic GGAA-
microsatellite. To identify candidate genes with high clinical
relevance, we crossed two datasets. The first comprised expression
microarrays of A673 EwS cells harboring a doxycycline (DOX)-
inducible shRNA against EWSR1-FLI1 (A673/TR/shEF1) profiled
with/without DOX-treatment (Supplementary Data 1). The second
comprised 166 transcriptomes of primary EwS with clinical
annotation (Supplementary Data 2). We calculated for each gene
represented in both datasets the fold change (FC) of its expression
after DOX-induced EWSR1-FLI1 knockdown in A673/TR/
shEF1 cells and the significance for association with overall survival
(OS) stratifying patients by expression quintiles of the corre-
sponding gene. Specifically, the latter analysis was carried out by a
custom software (GenEx) that automatically calculates the P values
for each gene in a given overall survival dataset with matched gene
expression data by a Mantel–Haenszel test for patients grouped in
the highest versus the lowest expression quintile of the given gene
(adjusted for multiple comparisons by the Bonferroni method) (see
Methods). This analysis identifiedMYBL2 (alias B-MYB), encoding
a central transcription factor regulating cell proliferation, cell sur-
vival, and differentiation20, as the top EWSR1-FLI1 upregulated
gene, whose high expression was significantly associated with poor
OS (nominal P= 9.6×10−7, Bonferroni-adjusted P= 0.018)
(Fig. 1a, b; Supplementary Data 3).
The EWSR1-FLI1-dependency of MYBL2 expression was
validated in time-course experiments in A673/TR/shEF1 on the
mRNA and protein level in vitro and in vivo (Fig. 1c,
Supplementary Fig. 1a–c), and in nine additional cultured EwS
cell lines (Supplementary Fig. 1d).
Despite this tight regulation of MYBL2 by EWSR1-FLI1, we
noted a marked inter-tumor heterogeneity of MYBL2 mRNA
expression in 166 primary EwS (Supplementary Fig. 1e) and in an
independent cohort of 208 EwS on protein level stained for p-
MYBL2 (Supplementary Fig. 1f). Interestingly,MYBL2 expression
did not correlate with minor variations of EWSR1-FLI1
expression (Supplementary Fig. 1g), suggesting that inter-
individual diversity of MYBL2 transcription may be caused
differently.
In accordance, re-analysis of published chromatin immuno-
precipitation followed by next-generation sequencing (ChIP-seq)
data from A673 and SK-N-MC EwS cells21,22 revealed strong
signals for EWSR1-FLI1 that mapped to a polymorphic GGAA-
microsatellite located ~150 kb telomeric of MYBL2 (Fig. 1d). In
both cell lines, this GGAA-microsatellite exhibited EWSR1-FLI1-
dependent epigenetic characteristics of an active enhancer
indicated by H3K4me1 and H3K27ac marks (Fig. 1d). The
EWSR1-FLI1-dependent enhancer activity of this GGAA-
microsatellite was confirmed in reporter assays, for which we
cloned fragments of ~880 bp from cell line-derived haplotypes
differing in their number of consecutive GGAA-repeats (6, 10, or
12 GGAA-repeats) in the pGL3-Fluc vector. Other regulatory
variants in the flanking regions were excluded by whole-genome
sequencing (WGS) of the parental cell lines and by Sanger
sequencing of the cloned fragments (see Methods). In these
assays, we observed a positive correlation of the measured
enhancer activity and the number of consecutive GGAA-repeats
(Fig. 1e).
To test whether EWSR1-FLI1 prefers haplotypes with more
consecutive GGAA-repeats, we carried out ChIP-seq analysis
using relatively long reads (single-end 150 bp) for EWSR1-FLI1 in
the EwS cell line RDES that is heterozygous at the MYBL2-
associated GGAA-microsatellite (12 versus 14 consecutive
GGAA-repeats). In this analysis, we obtained 31 ChIP-seq reads
spanning the entire GGAA-microsatellite. In line with our results
from reporter assays (Fig. 1e), 71% of these spanning reads (22/
31) mapped to the longer haplotype, whereas only 29% (9/31)
mapped to the shorter one (P= 0.015).
Applying the haplotype inference and phasing for short
tandem repeats (HipSTR)23 algorithm on 38 pairs of germline
and EwS tumor WGS data covering the MYBL2-associated
GGAA-microsatellite6,12, we identified additional haplotypes with
6–17 consecutive GGAA-repeats (average 13.1 GGAA-repeats).
Notably, all haplotypes (76/76) were entirely conserved between
germline and tumor DNA (Supplementary Data 4).
We next performed expression quantitative trait locus (eQTL)
analysis in 35 primary EwS tumors for which matched gene
expression and WGS data were available. Prior reports suggested
that more than 13 consecutive GGAA-repeats at EWSR1-FLI1
bound GGAA-microsatellites delineate a critical number beyond
which very strong EWSR1-FLI1 binding and enhancer activity
can be observed16,19,24, which is in agreement with our ChIP-seq
analysis showing preferential EWSR1-FLI1 binding to the longer
haplotype as stated above. Classifying all haplotypes in either
“short” (≤13 GGAA-repeats) or “long” (>13 GGAA-repeats), we
detected a significantly higher MYBL2 expression in EwS tumors
with long/long haplotypes compared to those with short/short
haplotypes (Supplementary Data 4, Supplementary Fig. 1h).
We further validated the EWSR1-FLI1-mediated regulation of
MYBL2 in time-course EWSR1-FLI1 ChIP-seq and RNA sequen-
cing (RNA-seq) data generated in A673/TR/shEF1 cells25. Removal
of DOX after suppression of EWSR1-FLI1 for 7 days led to a
gradual increase of MYBL2 transcription that correlated with
increasing EWSR1-FLI1 recruitment to this GGAA-microsatellite
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(rPearson= 0.816). Strikingly, targeting this GGAA-microsatellite by
clustered regularly interspaced short palindromic repeats inter-
ference (CRISPRi)26–28 in highly MYBL2 expressing RDES cells
strongly suppressed MYBL2 transcription (Fig. 1f) and induced a
potentially counter-regulatory upregulation of EWSR1-FLI1 (Sup-
plementary Fig. 1i). Interestingly, these cells showed a significantly
decreased cell growth relative to controls (Supplementary Fig. 1j).
Together, these findings indicate that MYBL2 is a clinically
relevant direct EWSR1-FLI1 target gene, whose expression can be
modulated by EWSR1-FLI1 binding to a polymorphic enhancer-
like GGAA-microsatellite.
MYBL2 is critical for proliferation and cell survival of EwS
cells. To obtain first clues on the functional role of MYBL2 in
primary EwS, we performed gene-set enrichment analysis (GSEA)
of MYBL2 co-expressed genes in 166 EwS tumors. GSEA revealed
that MYBL2 co-expressed genes were strongly enriched in human
orthologs of known MYBL2 targets in zebrafish29 and in sig-
natures related to proliferation30, cell cycle progression31, and
sensitization to apoptosis mediated by a CDK-inhibiting pro-
tein32 (Fig. 2a, Supplementary Data 5), suggesting that MYBL2
may constitute a key downstream mediator of EWSR1-FLI1-
induced, evolutionary conserved proliferation programs.
To test this hypothesis, we performed MYBL2 knockdown
experiments in A673, SK-N-MC, and RDES EwS cell lines with
moderate to high baseline MYBL2 expression (Supplementary
Fig. 2a–c). Using four different siRNAs, we found that MYBL2
silencing reduced proliferation through blockage of G2/M
progression, which was accompanied by increased apoptotic cell
death (Fig. 2b–d).
To further explore the function of MYBL2 in EwS growth, we
generated DOX-inducible anti-MYBL2 shRNA expression sys-
tems in A673 and SK-N-MC cells using two different shRNAs. In
both cell lines, DOX-induced MYBL2 silencing significantly
reduced clonogenic growth in vitro and tumor growth in vivo
compared to a non-targeting control shRNA (Fig. 2e–g,
Supplementary Fig. 2d–g). In line with our transient knockdown
experiments, we observed an increased number of stalled mitoses,
indicating G2/M blockage, and more apoptotic tumor cells
positive for cleaved caspase 3 in MYBL2-silenced xenografts
(Fig. 2h, i). Collectively, these findings indicate that MYBL2 is a
critical pro-proliferative downstream effector of EWSR1-FLI1
required for proper G2/M transition and cell survival.
MYBL2 mediates its phenotype via upregulation of CCNF,
BIRC5, and AURKB. To identify potential direct MYBL2 targets
that could explain its pro-proliferative effect, we sequenced RNA
of three EwS cell lines with/without MYBL2 knockdown (Fig. 3a).
Consistent with our enrichment analyses in primary EwS and
functional experiments, GSEA of the identified differentially
expressed genes (DEGs) showed thatMYBL2 suppression leads to
a strong downregulation of the same gene sets comprising human
orthologs of zebrafish MYBL2 targets and identical proliferation,
cell cycle, and sensitization to CDK-inhibitor mediated apoptosis
gene signatures (Fig. 3b, Supplementary Fig. 3a, Supplementary
Data 6).
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Fig. 1 MYBL2 is a clinically relevant direct EWSR1-FLI1 target gene regulated via a polymorphic GGAA-microsatellite. a Integrative analysis of gene
expression microarrays of A673/TR/shEF1 cells profiled with/without DOX addition with 166 clinically annotated EwS transcriptomes; P values determined
via Mantel–Haenszel test. The dashed line indicates the Bonferroni-adjusted P value threshold. b Kaplan-Meier survival analysis of 166 EwS patients
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A673/TR/shEF1 cells. EWSR1-FLI1 was silenced for 7 days by DOX-treatment and re-expressed after DOX-removal for 10 days. Loading control: β-actin.
d Epigenetic profile of the MYBL2 locus in indicated EwS cells transduced with either a control shRNA (shGFP) or a specific shRNA against EWSR1-FLI1
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the SEM, n≥ 3 biologically independent experiments. ***P < 0.001, **P < 0.01, *P < 0.05; P values determined via two-tailed Mann–Whitney test. Source
data are provided as a Source Data file
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We then focused on the 76 most significantly DEGs (mean log2
FC |≥1.5|, Bonferroni-adjusted P < 0.05), of which representative
genes were validated by quantitative real time PCR (qRT-PCR)
(Supplementary Fig. 3b, c, Supplementary Data 7). ChIP-seq
analysis using a specific anti-MYBL2 antibody revealed that 50 of
these 76 DEGs (66%) showed evidence for MYBL2 promoter-
binding (Fig. 3c, Supplementary Data 8). Using microarray data
of 166 patient tumors in which 92% of these direct MYBL2 targets
were represented enabled correlation of their expression levels
with that of MYBL2 and with OS of patients stratified by median
expression of the corresponding gene (Supplementary Data 9,
10). Among these genes, CCNF, BIRC5, and AURKB stood out for
being highly significantly co-expressed with MYBL2 (Bonferroni-
adjusted P < 0.05, rPearson ≥ 0.7) (Fig. 3d), and associated with
poor OS (Fig. 3e). To investigate their functional role, we
individually knocked down either gene using two specific siRNAs
in two different EwS cell lines (Supplementary Fig. 3d) and
assessed proliferation and cell viability in vitro. Strikingly,
knockdown of these genes broadly phenocopied the anti-
proliferative and anti-survival effect of MYBL2 silencing
(Fig. 3f, g), suggesting that they may constitute important
mediators of the pro-proliferative EWSR1-FLI1/MYBL2 tran-
scriptional program. However, as other functionally relevant
genes (e.g. MKI67, KIF20A, PIF1) are also regulated by MYBL2
(Supplementary Fig. 3c), it is conceivable that other genes may
contribute to the phenotype of MYBL2.
High MYBL2 levels sensitize EwS cells toward CDK2 inhibi-
tion. As there are—to the best of our knowledge—currently no
direct MYBL2 inhibitors available, we reasoned that targeting its
major upstream cyclin dependent kinase, CDK2, which activates
MYBL2 through phosphorylation20, may offer a new therapeutic
option for EwS patients with high MYBL2 expression. To test this
possibility, we treated EwS cells with two small-molecule CDK2
inhibitors (CVT-313 and NU6140). While both inhibitors strongly
reduced growth of A673 EwS cells at the lower micro-molar range,
sensitivity toward them was dramatically diminished when
MYBL2 was suppressed (Fig. 4a). Such differential effect was not
observed in control cells expressing a non-targeting shRNA
(Fig. 4a). Notably, NU6140 is a dual inhibitor of CDK2 and the
major downstream MYBL2 target AURKB. Since this inhibitor
enabled to specifically target EwS cells up- and downstream of
MYBL2, we tested its effect on EwS growth in vivo. Treatment of
NOD/scid/gamma (NSG) mice with NU6140 significantly (P <
0.05) reduced growth of EwS xenografts compared to vehicle
(DMSO) (Fig. 4b), and was accompanied by reduced levels of
phosphorylated MYBL2 and increased apoptotic cell death
(Fig. 4c). However, this inhibitor had no additional effect on
growth of xenografts with silenced MYBL2 expression (Fig. 4b),
suggesting that MYBL2 is important for the anti-proliferative
effect of CDK2 inhibitors. Consistently, different EwS cell lines
with highMYBL2 levels showed higher sensitivity toward NU6140
than a EwS cell line with constitutively low MYBL2 expression
(Supplementary Fig. 4a, b). A similar effect on growth of A673
EwS xenografts was observed using the CDK2 inhibitor CVT-313
(Supplementary Fig. 4c, e). Since we neither observed significant
weight loss (Supplementary Fig. 4d) nor histomorphological
changes in inner organs in mice treated for 14 days with up to
40mg kg−1 of either inhibitor, these results indicated that CDK2
inhibition can safely impair growth of EwS tumors and that
MYBL2 may serve as a biomarker to predict its efficacy.
Interestingly, we observed in A673/TR/shEF1 cells that CDK2
appears to be moderately upregulated by EWSR1-FLI1 (Supple-
mentary Fig. 4f), and found evidence for binding of EWSR1-FLI1
at the CDK2 locus in EwS cells (Supplementary Fig. 4g). However,
whether EWSR1-FLI1 regulates CDK2 expression directly or
indirectly remains to be elucidated in future studies.
Discussion
Collectively, our discoveries made in an aggressive childhood
cancer exemplify how oncogenic cooperation between a cancer
driver-mutation (here EWSR1-FLI1) and a regulatory germline
variant (here a polymorphic enhancer-like GGAA microsatellite)
can create a major source of inter-tumor heterogeneity deter-
mining clinical outcome and drug response through modulation
of a druggable key downstream player (Fig. 4d).
To explore the possibility of such oncogenic cooperation in
EwS beyond MYBL2, we analyzed the top five additional hits of
our initial screen whose high expression was associated with
worse patient overall survival (EXO1, C1ORF112, ESPL1, HJURP,
RAD54L; Supplementary Data 3) for the presence of EWSR1-
FLI1 bound GGAA-microsatellites or ETS-like binding motifs in
the vicinity of these genes, and in that case also possible eQTL
effects. While no EWSR1-FLI1 binding was observed at the
ESPL1 locus, we found evidence for EWSR1-FLI1 binding at
GGAA-microsatellites or ETS-like single GGAA-motifs at the
other loci. However, most of these EWSR1-FLI1-binding sites did
not show genetic variability in WGS data from primary EwS
samples, and if so, they appeared to have no eQTL properties
(Supplementary Fig. 5), which may further support the special
role of MYBL2 in EwS.
Our results suggest that cooperation between disease-
promoting somatic mutations and regulatory germline variants
could constitute a general mechanism to explain diversity of
disease phenotypes, possibly beyond cancer. In line with this idea,
recent reports for neurodegenerative and metabolic diseases
showed that the same disease-causing somatic event/mutation
can induce distinct phenotypes depending on (inherited) varia-
tions in regulatory elements7,33,34. We anticipate that our findings
made in the EwS model are translatable to other malignancies,
and propose that integration of the regulatory genome in the
process of developing new predictive markers and therapeutic
strategies is necessary to refine and fully exploit “omics”-based
precision medicine.
Methods
Provenience of cell lines and cell culture conditions. A673 and HEK293T cells
were purchased from American Type Culture Collection (ATCC). MHH-ES1,
RDES, RH1, SK-ES1, and SK-N-MC cells were provided by the German Collection
of Microorganisms and Cell Cultures (DSMZ). TC-32, TC-71, and CHLA-10 cells
were kindly provided by the Children’s Oncology Group (COG) and EW1, EW3,
EW7, EW16, EW17, EW18, EW22, EW23, EW24, LAP35, MIC, ORS, POE, STA-
ET1, STA-ET8 cells were provided by O. Delattre (Institute Curie, Paris). A673/
TR/shEF1 cells were kindly provided by J. Alonso (Madrid, Spain)35. The SK-N-
MC cell line is listed in the database of commonly misidentified cell lines, ICLAC
(http://iclac.org/databases/cross-contaminations), as it was initially described to be
a neuroblastoma cell line. Indeed, it is a EwS cell line expressing the pathogno-
monic fusion oncogene EWSR1-FLI1. All cell lines were grown in humidified
atmosphere at 37 °C and 5% CO2. Cells were cultured in RPMI 1640 medium
supplemented with stable glutamine (Biochrom), 10% tetracycline-free FCS
(Sigma-Aldrich), 100 Uml−1 penicillin (Biochrom), and 100 µg ml−1 streptomycin
(Biochrom). Cells were routinely checked by nested PCR for mycoplasma infection,
and their purity was confirmed by STR-profiling and, if applicable, by PCR-based
detection of specific fusion oncogenes.
DNA/RNA extraction, reverse transcription, and qRT-PCR. DNA was extracted
with the NucleoSpin Tissue kit (Macherey-Nagel); plasmid DNA was extracted
from bacteria with the PureYield kit (Promega). RNA extraction was performed
with the NucleoSpin RNA kit (Macherey-Nagel) and RNA was reverse transcribed
using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems).
qRT-PCRs were performed using SYBR Select Master Mix (Applied Biosystems)
and reactions were run on a Bio-Rad CFX Connect instrument and analyzed using
the Bio-Rad CFX Manager 3.1 software. All oligonucleotides were purchased from
MWG Eurofins Genomics. For primer sequences see Supplementary Data 11.
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Transient transfection. For siRNA transfection, cells were seeded in a six-well
plate at a density of 1.5 × 105 per well in 1.6 ml of growth medium. The cells were
transfected with either a negative control non-targeting siRNA (Sigma-Aldrich
MISSION siRNA Universal Negative Control #1) or specific siRNAs (25–65 nM,
depending on the cell line and the siRNA) and HiPerfect (Qiagen). Cells were
retransfected 48 h after the first transfection and harvested 96 h after the first
transfection. siRNA sequences are given in Supplementary Data 11. For plasmid
transfection, cells were seeded in a six-well plate at a density of 2 × 105 per well in
1.8 ml of growth medium. Plasmids were transfected with Lipofectamine LTX and
Plus Reagent (Invitrogen). The pGL3 vector used for reporter assays has been
described before16.
Doxycycline (DOX)-inducible shRNA constructs. Either a non-targeting
negative control shRNA (MWG Eurofins Genomics) or specific shRNAs tar-
geting EWSR1-FLI1 or MYBL2 (both MWG Eurofins Genomics) were cloned in
the pLKO-Tet-on-all-in-one system36. Oligonucleotide sequences are given in
Supplementary Data 11. Lentiviruses were produced in HEK293T cells. A673 and
SK-N-MC EwS cells were infected with respective lentiviruses and selected with
1.5 µg ml−1 puromycin (Invivogen). After single-cell cloning, knockdown effi-
cacy of individual clones was assessed by qRT-PCR 48 h after addition of DOX
(1 µg ml−1; Sigma-Aldrich).
DNA constructs and reporter assays. MYBL2-associated GGAA-microsatellites
(with ~440 bp 5′ and 3′ flanking regions) from three EwS cell lines were PCR-
cloned upstream of the SV40 minimal promoter into the pGL3-Fluc vector (Pro-
mega)16. Primer sequences are given in Supplementary Data 11. The presence of
additional variants devoid of the GGAA-microsatellite was ruled out by WGS of
the parental cell lines and Sanger sequencing of the cloned fragments. A673/TR/
shEF1 cells (2 × 105 per well) were transfected with the Firefly pGL3-Fluc vector
containing respective microsatellites and the Renilla pGL3-Rluc vector (Promega)
(ratio 100:1) in a six-well plate with 1.8 ml of growth medium. Four hours after
transfection, transfection medium was replaced by medium with/without DOX
(1 µg ml−1; Sigma-Aldrich). Cells were lysed and assayed with a dual luciferase
assay system (Berthold) after 72 h. Firefly luciferase activity was normalized to that
of Renilla.
CRISPR interference (CRISPRi) and analysis of cell growth. Due to the lack of
functional DNAse, CRISPRi does not cause a knockout of the targeted DNA
sequence, but blocks protein binding to it26,28. For the reported experiments, a
DNAse-dead CAS9 (dCAS9) fused to the KRAB effector domain, which promotes
an inhibiting chromatin state, is targeted to the genomic region of interest by
specific gRNAs to silence the activity of a given enhancer26,28. To achieve this, we
used a pHAGE TRE dCas9-KRAB vector (Addgene #50917) and a pLKO.1-puro
U6 sgRNA BfuAI large stuffer vector (Addgene #52628), the latter containing
either two gRNAs, targeting sequences adjacent to the MYBL2-associated GGAA-
microsatellite, or a scrambled control (Supplementary Data 11). Lentivirus pro-
duction was performed in HEK293T cells. RDES EwS cells were infected with the
respective lentiviruses and selected with 1 µg ml−1 puromycin and 1.5 µg ml−1
G418 (both Invivogen). The cells were induced with DOX (1 μg ml−1; Sigma-
Aldrich) for 5 days, after which MYBL2 and EWSR1-FLI1 levels were measured by
qRT-PCR.
For measurement of cell growth, cells were grown in medium containing
selection antibiotics and DOX (2 µg ml−1) for 14 days as described37. Thereafter,
8 × 104 cells/well were plated in quadruplicate wells of 24-well plates in the
presence of DOX. After four additional days, cells were washed and fixed with
trichloroacetic acid for 1 h at 4 °C. Then, plates were washed with phosphate-
buffered saline (PBS), air dried, and cells were stained with crystal violet (Sigma-
Aldrich) for 30 min. Surplus crystal violet was removed by rinsing the plates with
PBS. Cell-bound crystal violet was dissolved in 10% acetic acid, and optical density
was measured at 595 nm in a DS-11 spectrophotometer (DeNovix Inc.).
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Fig. 4 High MYBL2 expression levels sensitize EwS cells toward treatment with CDK2 inhibitors in vitro and in vivo. a Analysis of IC50 of CDK2 inhibitors
CVT-313 and NU6140 in A673 cells containing either DOX-inducible specific shMYBL2 or non-targeting shControl constructs. Horizontal bars represent
means, and whiskers represent the SEM, n≥ 3 biologically independent experiments; P values determined via two-tailed Mann–Whitney test. b Left:
Schematic of the experimental setting of CDK2 inhibitor treatment (NU6140) in vivo. NSG mice were xenografted with A673 cells containing a DOX-
inducible shMYBL2 construct, treated with/without DOX and either vehicle or NU6140 in a dose of 20mg kg−1 or 40 mg kg−1. Mice were randomized to
the treatment groups when tumors were palpable. Right: For each condition the mean tumor volume and SEM of 4–6 mice over the time of treatment are
shown; P values determined via two-tailed Mann–Whitney test. c Left: Representative IHC micrographs of p-MYBL2 and cleaved caspase 3 (CC3) staining
of A673/TR/shMYBL2 xenografts (DOX (–)) treated with either vehicle or NU6140. Scale bar is 100 µm. Right: Quantification of positivity for p-MYBL2
and CC3, respectively. Horizontal bars represent medians or means, and whiskers interquartile ranges or SEM for p-MYBL2 or CC3, respectively,
n≥4 samples per condition; P values determined via Kruskal–Wallis test (p-MYBL2) or two-tailed Mann–Whitney test (CC3). d Model of EWSR1-FLI1-
dependent regulation of MYBL2 via the MYBL2-associated GGAA-microsatellite in EwS. Not significant, ns; ***P < 0.001, **P < 0.01, *P < 0.05. Source data
are provided as a Source Data file
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Western blot. Protein from A673/TR/shEF1 cells was extracted at d0, d7, d11, d14,
and d17 with RIPA and anti-protease cocktail (Roche). Western blots were per-
formed following routine protocols and specific band detection was achieved by the
use of rabbit monoclonal anti-FLI1 antibody (1:1000, ab133485; Abcam)38, rabbit
polyclonal anti-MYBL2 antibody (1:500, sc-725; Santa Cruz)39, and mouse
monoclonal anti-ß-actin (1:10,000, A-5316; Sigma-Aldrich). Anti-rabbit IgG
horseradish peroxidase-coupled antibody (1:3000, Amersham Bioscience) and anti-
mouse IgG horseradish peroxidase coupled antibody (1:3,000; Amersham
Bioscience) was used as secondary antibody. Proteins were visualized using che-
miluminescence (Pierce ECL Western blot chemiluminescent substrate; Thermo
Fisher Scientific).
Proliferation assays. Cells were seeded in a six-well plate at a density of 1.5 × 105
per well in 1.6 ml of growth medium. The cells were transfected with either a
negative control non-targeting siRNA in duplicate wells (Sigma-Aldrich MISSION
siRNA Universal Negative Control #1) or up to four specific siRNAs (MWG
Eurofins Genomics) (25–65 nM, depending on the cell line and siRNA) using
HiPerfect (Qiagen). siRNA sequences are given in Supplementary Data 11.
Retransfection was performed 48 h after the first transfection. Ninety-six hours
after the first transfection, cells were harvested (including supernatant), stained
with Trypan blue (Sigma-Aldrich), and counted in a standardized hemocytometer
(C-Chip, NanoEnTek).
Analysis of cell cycle and apoptosis. Analysis of cell cycle phases was performed
by propidium iodide (PI) (Sigma-Aldrich) staining. Cells were transfected with
siRNAs equivalently to the proliferation assays (see above), harvested after 96 h
(including supernatant), fixed in ethanol (70%) at 4 °C, and stained with PI solu-
tion (50 µg ml−1, with 20 µg ml−1 RNAse A (Invitrogen)). Analysis of apoptosis
has been performed by combined Annexin V-FITC/PI staining (BD Pharmingen
FITC Annexin V Apoptosis Detection Kit II; BD Biosciences). Cells were trans-
fected with siRNAs equivalently to the proliferation assays (see above) and har-
vested after 96 h (including supernatant). The samples were assayed on an Accuri
C6 flow cytometer and analyzed with the Accuri C6 CFlow Plus software. An
example of the gating strategy is given in Supplementary Fig. 6.
Colony-forming assays. A673 and SK-N-MC cells containing either a DOX-
inducible non-targeting control shRNA or MYBL2-targeting specific shRNAs were
seeded in triplicate wells of a 12-well plate at a density of 500 cells (A673) or 1000
cells (SK-N-MC) per well in 2 ml of growth medium. Cells were grown with/
without DOX (1 µg ml−1; Sigma-Aldrich) for 10–14 days depending on the cell line
and afterwards stained with crystal violet (Sigma-Aldrich). Colony number was
determined on scanned plates using Fiji (ImageJ)40,41.
cDNA library and RNA sequencing (RNA-seq). A673, SK-N-MC, and RDES
EwS cell lines were transfected in triplicates with either a negative control non-
targeting siRNA or a specific siRNA targeting MYBL2 (siMYBL2_1). Total RNA
was extracted using the NucleoSpin II kit (Macherey-Nagel). Complementary DNA
libraries were sequenced with an Illumina HiSeq2500 instrument using 150 bp
paired-end sequencing. Obtained reads were aligned on the human genome (hg19)
using TopHat (version 2.0.6)42. Counting of reads on annotated genes from the
GRCh37 gene build was done using htseq-count (v. HTSeq-0.5.3p9)43 with the
following parameters: htseq-count -a 10 -q -s no -m union. Sample-to-sample
normalization and differential expression analyses were performed using the R
package DESeq2 (v.1.18.0)44. RNA-seq data were deposited at the Gene Expression
Omnibus (GEO; accession code GSE119972).
Chromatin immunoprecipitation and sequencing (ChIP-seq). DNA–protein
cross-linking was done in the presence of 1% of paraformaldehyde on 12 × 106
A673 or 4 × 106 RDES cells, respectively, for each condition for 10 min. Cell lysis,
chromatin shearing, immunoprecipitation, and DNA purification were performed
with reagents from iDeal ChIP-seq kit for Transcription Factors (Diagenode, ref:
C01010054). Chromatin shearing was carried out in a Bioruptor (Diagenode) using
20 cycles of sonication (30 s high, 30 s off) in TPX tubes (Diagenode, ref: 50001).
For immunoprecipitation of activated MYBL2, 2 µg of a monoclonal ChIP-grade
rabbit anti-p-MYBL2 antibody (Abcam, ab76009, lot GR113270–6)45 were used.
MYBL2 ChIP and input were sequenced on an Illumina HiSeq2500 instrument
(100 bp single-end). For immunoprecipitation of EWSR1-FLI1, 2 µg of a polyclonal
ChIP-grade rabbit anti-FLI1 antibody (Abcam, ab15289, lot GR293950-1)18 was
used. EWSR1-FLI1 ChIP and input were sequenced on an Illumina HiSeq2500
instrument (150 bp single-end). ChIP-seq reads were aligned to the human genome
(hg19 version) with Bowtie2 (ref. 46). Peaks were called with MACS2 with option
narrow47. To normalize, we took the input dataset from the same cell line. PAVIS
was used for peak annotation and visualization48. For analysis of the number of
EWSR1-FLI1 ChIP-seq reads spanning the different haplotypes of the MYBL2-
associated GGAA-microsatellite in RDES cells, exclusively the spanning reads were
extracted from the BAM file with SAMtools, and mapped to the corresponding
haplotype according to CIGAR scores49. Significance levels were calculated using a
binomial test (p= 0.5). ChIP-seq data concerning MYBL2 were deposited at the
GEO (accession code GSE119972).
Analysis of published ChIP-seq and DNAse-seq data. Publicly available
ENCODE SK-N-MC DNAse-seq data (GSM736570) and pre-processed A673 and
SK-N-MC ChIP-seq data (GSE61944) were retrieved from the GEO and displayed
in the UCSC genome browser. Samples used: GSM1517544 SK-N-
MC_shGFP_48h_FLI1; GSM1517553 SK-N-MC_shFLI1_48h_FLI1; GSM1517569
A673_shGFP_48h_FLI1; GSM1517572 A673_shFLI1_48h_FLI1; GSM1517548 SK-
N-MC_shGFP_96h_H3K4me1; GSM1517557 SK-N-MC_shFLI1_96h_H3K4me1;
GSM1517545 SK-N-MC_shGFP_48h_H3K27ac; GSM1517554 SK-N-
MC_shFLI1_48h_H3K27ac; GSM1517568 A673 whole-cell extract (WCE).
CDK2 inhibitor assays in vitro. Cells were seeded in a 96-well plate at a density of
5 × 103 per well. In case of cells containing DOX-inducible constructs, cells were
treated with/without DOX (1 µg ml−1; Sigma-Aldrich). Twenty-four hours after
seeding or pre-incubation with DOX, respectively, CDK2 inhibitors (CVT-313 or
NU6140; Merck and Tocris) were added in serially diluted concentrations ranging
from 0.001 to 100 µM. Each well contained an equal concentration of 0.5% DMSO
(Sigma-Aldrich). Cells only treated with 0.5% of DMSO served as a control. After
72 h of inhibitor treatment, the plates were assayed on a Thermo Fisher Varioskan
plate reader after incubation with Resazurin (20 µg ml−1; Sigma-Aldrich) for 6 h.
Xenotransplantation and CDK2 inhibitor treatment in vivo. All mouse experi-
ments were approved by the local authorities in compliance with all relevant ethical
regulations (including, but not limited to, tumor size). Sample size was pre-
determined using power calculations with β= 0.8 and α = 0.05 based on preliminary
data and in compliance with the 3 R system (replacement, reduction, refinement).
3 × 106 A673 and SK-N-MC cells, containing either a DOX-inducible negative
control shRNA or specific shRNAs against EWSR1-FLI1 or MYBL2, were injected
subcutaneously with a 1:1 mix of PBS (Biochrom) and Geltrex (LDEV-Free Reduced
Growth Factor Basement Membrane Matrix, Thermo Fisher Scientific; max volume
100 µl) in the right flanks of 3–9 months old female or male NSG mice (Charles
River Laboratories). For shRNA sequences see Supplementary Data 11. When
tumors were palpable, mice were randomized to the control group (17.5mgml−1
sucrose (Sigma-Aldrich) in drinking water) or the treatment group (2mgml−1 DOX
(Beladox, bela-pharm) and 50mgml−1 sucrose (Sigma-Aldrich) in drinking water).
Tumor size was measured with a caliper every 2 days and tumor volume was
calculated as V= a × b2/2 with a being the largest diameter and b being the smallest
diameter. Once the tumors reached a volume of 1500mm3 respective mice were
sacrificed by cervical dislocation. Other humane endpoints were determined as fol-
lows: Ulcerated tumors, loss of 20% body weight, constant curved or crouched body
posture, bloody diarrhea or rectal prolapse, abnormal breathing, severe dehydration,
visible abdominal distention, obese Body Condition Scores (BCS), apathy, and self-
isolation. For CDK2 inhibitor treatment in vivo, cells were injected as described
above. When tumors were palpable, mice were assigned to either the vehicle (DSMO)
or a treatment group (20 or 40mg kg−1), each with or without addition of DOX to
the drinking water (2mgml−1 DOX; Beladox, bela-pharm). In case of CVT-313
(Tocris) treatment, DOX was not applied. The CDK2 inhibitors NU6140 or CVT-
313 (both Tocris) were administered i.p. for 12 days, with a break of 1 day every
4 days of treatment. The experimental endpoint was predetermined as 14 days after
first injection of either inhibitor, or if humane endpoints as described above were
reached before. To check histomorphological changes of inner organs upon CDK2
inhibitor treatment, we examined hematoxylin and eosin (HE) stained slides of heart,
lungs, liver, stomach, pancreas, intestines, kidneys, adrenal glands, bone marrow, and
spleen from treated and non-treated mice. Tumor tissues were subjected to HE
staining, as well as immunohistochemical staining for p-MYBL2 and cleaved caspase
3 (as described below). Animal experiments were approved by the government of
Upper Bavaria and conducted in accordance with ARRIVE guidelines, recommen-
dations of the European Community (86/609/EEC), and UKCCCR (guidelines for
the welfare and use of animals in cancer research).
Survival analysis. Microarray data of 166 primary EwS tumors (GSE63157,
GSE34620, GSE12102, GSE17618) for which clinical annotations were available
were downloaded from the GEO. Data were either generated on Affymetrix HG-
U133Plus2.0 or on Affymetrix HuEx-1.0-st microarray chips and separately nor-
malized by RMA using custom brainarray chip description files (CDF, v20).
ComBat was used to remove batch effects50,51. Patients were stratified by their
quintile or median intra-tumoral gene expression levels. Mantel–Haenszel test was
performed to calculate significance levels, using either a custom code (GenEx) for
batch queries or GraphPad PRISM version 5 for individual genes (GraphPad
Software Inc., CA, USA). P values < 0.05 were considered as statistically significant.
Survival data were crossed with gene expression microarray data (Affymetrix HG-
U133A2.0) generated in A673/TR/shEF1 cells (GSE27524; 53 h DOX-treatment),
which were normalized as described above (RMA with brainarray CDF, v19).
Gene-set enrichment analysis. Using the Affymetrix gene expression dataset
comprising 166 primary EwS patients, enrichment of gene-sets that are among
MYBL2 co-regulated genes were identified by ranking of Pearson´s correlation
coefficient of the expression of every gene with MYBL2 expression and perfor-
mance of a pre-ranked GSEA with 1000 permutations52. Using the RNA-seq
dataset containing DEGs after siRNA-mediated MYBL2 knockdown compared to a
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non-targeting siControl in A673, SK-N-MC, and RDES EwS cell lines, all genes
were ranked by their mean log2 FC and a pre-ranked GSEA was performed with
1000 permutations52.
GGAA-microsatellite analysis using HipSTR. EwS tumors and/or matched blood
samples were collected with informed consent from EwS patients treated in the
Hospital for Sick Children (SickKids) in Toronto, Canada, in accordance with
Research Ethical Board (REB) guidelines (approval no. 1000053452). In addition,
publicly available EwS reference samples from the International Cancer Genome
Consortium (ICGC) with matched tumor/germline WGS data were used for
analysis6. WGS was performed in all tumors and available matched germline
samples using established protocols on Illumina instruments (paired-end 150/150
bp for the Toronto cohort, and paired-end 100/100 bp for the ICGC cohort).
Paired-end FASTQ files were aligned to the human genome (hg19/GRCh37) using
BWA-MEM (v.0.7.8). Indel realignment and base quality scores were recalibrated
using the Genome Analysis Toolkit (v.2.8.1). For the Toronto cohort, published
gene expression data were available from RNA-seq which was deposited at the
European Genome-phenome Archive (EGA) under accession number
EGAS00001003062; and for the ICGC cohort from matched Affymetrix HG-
U133A or HG-U133Plus2.0 gene expression arrays (GSE37371; GSE7007;
GSE34620). Affymetrix gene expression data were normalized separately for each
chip type by RMA53 using custom brainarray CDF (v20, ENTREZ)54. Batch effects
were removed using ComBat50,51. For eQTL analyses, only tumor samples with a
minimum tumor purity of >60%, corresponding to TCGA standard tissue
requirements (http://cancergenome.nih.gov/cancersselected/biospeccriteria), were
used. Tumor purity estimates were made using the AscatNGS (Toronto cohort)55
or the ESTIMATE algorithm (ICGC cohort)56. To call the genotypes of the
MYBL2-associated GGAA-microsatellite, we applied HipSTR (v.0.6.2)23 on the
WGS data using a minimum threshold of ten reads. All genotypes passed the
following HipSTR default filters: --min-call-qual 0.9; --max-call-flank-indel 0.15;
--max-call-stutter 0.15; --min-call-allele-bias -2; --min-call-strand-bias -2.
Human samples and ethics approval. Archived human tissue samples were
retrieved from the Institute of Pathology of the LMU Munich (Germany) and the
Gerhard-Domagk Institute of Pathology of the University Hospital of Münster
(Germany). All patients provided written informed consent. Retrospective and
blinded analysis of anonymized samples was carried out upon ethical approval of
LMU Munich’s ethics committee (approval no. 550-16 UE).
Tissue microarrays and immunohistochemistry. Formalin-fixed paraffin-
embedded samples were collected at the Institute of Pathology of the LMU
Munich57. We harvested at least two cores per sample with a core-diameter of
1 mm from all blocks to construct tissue microarrays. All EwS samples showed
cytogenetic evidence for a translocation of the EWSR1 gene either as determined by
fluorescence in situ hybridization and/or qRT-PCR. The samples were reviewed by
a reference pathologist. Four-micrometer sections were cut for immunohis-
tochemistry and antigen retrieval was performed with microwave treatment using
the antigen retrieval ProTaqs I Antigen-Enhancer (Quartett) for p-MYBL2 or the
Target Retrieval Solution (Agilent Technologies) for cleaved caspase 3. In total,
7.5% aqueous H2O2 solution (room temperature) and blocking serum from the
corresponding kits were used for 20 min for blockage of endogenous peroxidase.
Then slides were incubated for 60 min with the primary antibodies anti-p-MYBL2
(1:100 dilution; Abcam, ab76009) and anti-cleaved caspase 3 (1:100 dilution, Cell
Signaling, #9661). Afterwards slides were incubated with a secondary anti-rabbit
IgG antibody (MP-7401, ImmPress Reagent Kit, Peroxidase-conjugated) followed
by subsequent target detection using DAB+chromogen (Agilent Technologies).
Slides were counterstained with hematoxylin Gill’s Formula (H-3401; Vector).
Evaluation of immunoreactivity and quantification of mitoses. Evaluation of p-
MYBL2 immunostaining was carried out semi-quantitatively by a blinded observer
in analogy to the Immune Reactive Score (IRS), which is used routinely by
pathologists for quantification of hormone receptor expression in mammary car-
cinoma, ranging from 0 to 12 as described58. The intensity of p-MYBL2 immu-
noreactivity (score 0= none, score 1= low, score 2= intermediate, and score 3=
strong) and the percentage of cells stained with each intensity (score 0= 0%, score
1= 0–9%, score 2= 10–50%, score 3= 51–80%, and score 4= 81–100%) was
determined per high-power field (×40). The product of the predominant intensity
score and its percentage score defined the final IRS. For cleaved caspase 3
immunostaining, automated quantification of the percentage of positive high-
power field area was performed using Fiji (ImageJ)40,41. Mitoses were quantified in
HE-stained slides by a blinded observer per high-power field. Final scores/quan-
tifications were determined by examination of 4–16 high-power fields of at least
one section for each sample.
Statistical analysis and software. Statistical data analysis was performed using
GraphPad PRISM 5 (GraphPad Software Inc., CA, USA) on the raw data. If not
otherwise specified in the figure legends comparison of two groups in functional
in vitro experiments was carried out using a two-tailed Mann–Whitney test; ***P <
0.001, **P < 0.01, *P < 0.05. Comparison of three groups with data in ordinal scale
was performed using Kruskal–Wallis test. If not otherwise specified in the figure
legends, data are presented as dot plots with horizontal bars representing means, and
whiskers representing the standard error of the mean (SEM). Sample size for all
in vitro experiments was chosen empirically. In Kaplan–Meier survival analyses,
curves were calculated from all individual survival times of patients or mice,
respectively. Curves were compared by Mantel–Haenszel test to detect significant
differences between the groups. For in vivo experiments, sample size was pre-
determined using power calculations with β= 0.8 and α = 0.05 based on preliminary
data and in compliance with the 3R system (replacement, reduction, refinement).
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
RNA-seq and ChIP-seq data have been deposited at the Gene Expression Omnibus
(GEO) under the accession code GSE119972. Microarray data of 166 primary EwS
tumors are available from the GEO website under the accession codes GSE63157 (ref. 59),
GSE34620 (ref. 60), GSE12102 (ref. 61), GSE17618 (ref. 62). Survival data were crossed
with gene expression microarray data (Affymetrix HG-U133A2.0) generated in A673/
TR/shEF1 cells (GSE27524 (ref. 63); 53 h DOX-treatment). Publicly available ENCODE
SK-N-MC DNAse-seq data (GSM736570 (ref. 21)) and pre-processed A673 and SK-N-
MC ChIP-seq data (GSE61944 (ref. 22) were retrieved from the GEO and displayed in the
UCSC genome browser. The following samples were used: GSM1517544 SK-N-
MC_shGFP_48h_FLI1; GSM1517553 SK-N-MC_shFLI1_48h_FLI1; GSM1517569
A673_shGFP_48h_FLI1; GSM1517572 A673_shFLI1_48h_FLI1; GSM1517548 SK-N-
MC_shGFP_96h_H3K4me1; GSM1517557 SK-N-MC_shFLI1_96h_H3K4me1;
GSM1517545 SK-N-MC_shGFP_48h_H3K27ac; GSM1517554 SK-N-
MC_shFLI1_48h_H3K27ac; GSM1517568 A673 whole-cell extract (WCE). For gene
expression analysis of tumors for which matched germline/tumor WGS was available,
published gene expression data from the Toronto cohort was available from RNA-seq
which was deposited at the European Genome-phenome Archive (EGA) under accession
number EGAS00001003062(ref. 12); and for the ICGC cohort from matched Affymetrix
HG-U133A or HG-U133Plus2.0 gene expression arrays (GSE37371; GSE7007 (ref. 64);
GSE34620 (ref. 60)). The source data underlying Figs. 1a–c, 1e–f, 2a–g, 2i, 3a–b, 3d–g,
4a–c, and Supplementary Figs. 1a–b, 1d–j, 2a–d, 2g, 3a, 3c–d, 4a–g, and 5a–e are
provided as a Source Data file. All the other data supporting the findings of this study are
available within the article and its supplementary information files and from the
corresponding author upon reasonable request. A reporting summary for this article is
available as a Supplementary Information file.
Code availability
Custom code is available from the corresponding author upon reasonable request.
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